Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|WF-30917CD||NCORP-Wake Forest University||A Stepped-Care Telehealth Approach to Treat Distress in Rural Cancer Survivors||Cancer Prevention and Control CIRB||Available to Open|
|S1600||SWOG||A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes||Cancer Prevention and Control CIRB||Available to Open|
|PBTC-055||PBTC||Phase I/II trial of Dabrafenib, Trametinib, and Hydroxychloroquine (HCQ) for BRAF V600E-mutant or Trametinib and HCQ for BRAF fusion/duplication positive or NF1-associated recurrent or progressive gliomas in children and young adults||Pediatric CIRB||Available to Open|
|9853||ETCTN||A Phase 1 Study of AZD1775 in Combination with Belinostat in Relapsed and Refractory Myeloid Malignancies and Selected Untreated Patients with Acute Myeloid Leukemia||Adult CIRB - Early Phase Emphasis||Available to Open|
|NRG-BR001||RTOG||A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases||Adult CIRB - Early Phase Emphasis||Available to Open|
|E1910||ECOG||A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults||Adult CIRB - Late Phase Emphasis||Available to Open|
|ACNS1123||COG||Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT): A Groupwide Phase II Study||Pediatric CIRB||Available to Open|
|ANBL0532||COG||Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma: A Groupwide Phase III Study||Pediatric CIRB||Available to Open|
|ADVL1414||COG||A Phase 1 Study of Selinexor (KPT-330; IND #125052); A Selective XPO1 Inhibitor; In Recurrent and Refractory Pediatric Solid Tumors; Including CNS Tumors||Pediatric CIRB||Available to Open|
|A041703||Alliance||Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults with Relapsed or Refractory Disease||Adult CIRB - Late Phase Emphasis||Available to Open|